Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance
OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC.
Authors
- Takashi Yamanaka (ORCID: https://orcid.org/0000-0003-0117-5710)
- Junji Tsurutani (ORCID: https://orcid.org/0000-0002-6260-6943)
- Yoichi Higashibeppu
- Yuko Tanabe (ORCID: https://orcid.org/0000-0001-9279-5952)
- Michiko SUGAWARA (ORCID: https://orcid.org/0000-0001-8390-4010)
- Yohei Uchida
- Yukinori Sakata
- Hirofumi Mukai (ORCID: https://orcid.org/0000-0002-9292-5128)
- Masato Takahashi (ORCID: https://orcid.org/0000-0003-3265-0166)
- Kenichi Inoue (ORCID: https://orcid.org/0000-0003-2686-8732)
- Chiyomi Egawa
Institutions
- SHOWA Medical University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- Toranomon Hospital (JP)
- Kanagawa Cancer Center
- Eisai (Japan) (JP)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1111/ajco.14189
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eisai